Generic Name: nilotinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Tasigna is a kinase inhibitor approved for newly diagnosed or previously Philadelphia chromosome positive (Ph+) chronic myeloid leukemia.

General Info

Tasigna targets BCR-ABL, an abnormal tyrosine kinase produced by the Philadelphia chromosome mutation in people with chronic myeloid leukemia. It also inhibits other tyrosine kinases including platelet-derived growth factor receptor and c-KIT.

Studies showed that Tasigna prevents proliferation of blood cells that grow out of control in people with Ph+ chronic myeloid leukemia, including those who were previously treated with Gleevec (imatinib). It is also being tested for acute lymphoblastic leukemia and eosinophilic leukemia.


Dosing Info:

Tasigna is a capsule taken twice daily on an empty stomach. It may be used by both adults and children.

Side Effects

Common side effects include nausea, vomiting, diarrhea, headache, fatigue, joint pain, skin rash and itching. Gleevec can cause depletion of white blood cells (neutropenia) and platelets (thrombocytopenia), which can lead to infections and easy bleeding. Potentially serious side effects may include severe swelling or edema, heart, liver and pancreas problems and tumor lysis syndrome, a reaction that can occur when cancer cells die suddenly. Tasigna may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: November 29, 2018